The Tata Group-promoted Advinus Therapeutics is likely to license its diabetes molecule to other companies, according to Tata Sons executive director R Gopalakrishnan.

Advinus is set to initiate talks with pharma companies for further drug trials, he added.

Also Read   Related Stories News Now - Arvind Singhal: Textiles - The next hot sector - Tata Steel to raise up to $5.5 bn debt - Advinus develops molecule for diabetes - Ratan Tata conferred with Honorary Doctor of Laws - Advinus sees diabetes molecule breakthrough in six months - Reliance Cap buys 8.68% in Trent for Rs 21.2 cr

Also Read   Related Stories News Now - Markets end higher led by banks - No plans to review India aid, says UK - Budget likely to hike tax exemption to Rs 2 lakh - TCS to be IT partner of Europcar in France - Nalco Q3 net dips 80% to Rs 51 cr More

“Considering the past failures of other companies on this target, our discovery programme focused on identifying a molecule that would be efficacious without causing hypoglycemia; a side-effect associated with most compounds developed for this target,” said Rashmi Barbhaiya, managing director and chief executive officer of Advinus.

It is estimated that there are about 300 million adult (between 20 and 79 years) diabetics worldwide. It is also expected that by 2030, about 450 million people worldwide would be diabetics. Type II diabetes constitutes 85-95 per cent of all diabetes cases. In India itself it is estimated that there are about 51 million diabetics in 2010 and this number in all likelihood will go up to 80 million by 2030.

At present, five full-discovery programmes are on at Advinus for internal research. Advinus has a collaboration with Merck (US) for drug discovery in the area of metabolic diseases. The company has a drug discovery centre in Pune that focuses on diabetes, obesity, lipid disorders, inflammatory diseases and neglected diseases like dengue and malaria. Its Bangalore centre has a collaboration with DNDi (Drugs for Neglected), he said.

‘Golden Agri’ project
Tata Sons is also looking at augmenting its crop protection solution services and is looking at Japanese companies for collaboration. The group now has Tata chemicals for plant nutrients and Rallis India for crop protection.

“We are looking for a meaningful role in the seed segment, which is the missing link in the plant protection products business,’’ said Gopalakrishnan.

New Ipad Application :Business Standard's all new IPad App Click here to download for free Other Stories      - Markets end higher led by banks - No plans to review India aid, says UK - Budget likely to hike tax exemption to Rs 2 lakh - TCS to be IT partner of Europcar in France - Nalco Q3 net dips 80% to Rs 51 cr

Tags : Tata Group | Advinus Therapeutics | R Gopalakrishnan | pharma companies | Rashmi Barbhaiya | Type II diabetes | Drugs for Neglected   Read Business news in  Advertisements -  Save over Rs.3000 with IndianOil Citibank Card -  Now property search gets more exciting than ever before! -  Financial Learning now made easier and more convenient. -  Be part of it The World's Largest Aircraft. -  Only Developer to give a guarantee on time space & rate. -  Office 365 for professionals and small businesses. -  Buy Your Property with Our Triple Guarantee in India. -  Are You Serious About Your Future? Click here to know more -  Improve Patient Care & Experience. Click here to know more -  The loan is available at very competitive rates of interest. -   Introduce a New Automotive Luxury Car.. know more -  Making lives better through Social Innovation Business..